Gene expression in the bladder carcinoma rat model

Molecular Carcinogenesis

Volumn 41, Issue 2, 2004, Pages 69-76

  Ariel, Ilana ^a   Ayesh, Suhail ^b   Gofrit, Ofer ^a,b   Ayesh, Basim ^b   Abdul Ghani, Rula ^b   Pizov, Galina ^a   Smith, Yoav ^d   Sidi, Ami A ^c   Birman, Tatiana ^a   Schneider, Tamar ^b   De Groot, Nathan ^b   Hochberg, Abraham ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c WOLFSON MEDICAL CENTER   (Israel)

^d HEBREW UNIVERSITY   (Israel)

Author keywords

cDNA arrays; H19; Insulin like growth factor 2; N butyl N (4 hydroxybutyl) nitrosamine (BBN); Telomerase

Indexed keywords

DRINKING WATER; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; PROTEIN SUBUNIT; SOMATOMEDIN B; TELOMERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CONTROLLED STUDY; DNA MICROARRAY; DNA SEQUENCE; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC VARIABILITY; H19 PROTEIN; MICROMORPHOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PAPILLARY CARCINOMA; PREVALENCE; PRIORITY JOURNAL; RAT; TRANSITIONAL CELL CARCINOMA; TUMOR GROWTH; UPREGULATION;

ANIMALS; BUTYLHYDROXYBUTYLNITROSAMINE; CARCINOMA, TRANSITIONAL CELL; DISEASE MODELS, ANIMAL; DNA, COMPLEMENTARY; GENE EXPRESSION; GENE EXPRESSION PROFILING; INSULIN-LIKE GROWTH FACTOR II; MALE; RATS; RATS, WISTAR; RNA, UNTRANSLATED; TIME FACTORS; UP-REGULATION; URINARY BLADDER NEOPLASMS;

RATTUS NORVEGICUS;

EID: 5044225890     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.20046     Document Type: Article

References (41)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistic CA. Cancer J Clin 1997;47:5-27.
2. Hsieh JT, Dinney CP, Chung LW. The potential role of gene therapy in the treatment of bladder cancer. Urol Clin North Am 2000;27:103-113.
3. Wolf H, Kakizoe T, Smith PH, et al. Bladder tumors. Treated natural history. Prog Clin Biol Res 1986;221:223-255.
4. Prout GR, Jr., Barton BA, Griffin PP, Friedell GH. Treated history of noninvasive grade 1 transitional cell carcinoma. J Urol 1992;148:1413-1419.
5. Seigne JD. Gene therapy of bladder cancer. Cancer Control 1996;3:428-433.
6. Ito N, Hiasa Y, Tamai A, Okajima E, Kitamura H. Histogenesis of urinary bladder tumors by N-butyl-N-(4-hydroxybutyl)nitrosamine in rats. Gann 1969;60:401-410.
7. Kunze E, Schauer A. Morphology, classification, and histogenesis of N-butyl-N-(4-hydroxybutyl)nitrosamine induced carcinomas in the urinary bladder of rats. Z Krebsforsch 1977;88:273-289.
8. Ariel I, Sughayer M, Fellig Y, et al. The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma. Mol Pathol 2000;53:320-323.
9. Elkin M, Shevelev A, Schulze E, et al. The expression of the imprinted H19 and IGF-2 genes in human bladder carcinoma. FEBS Lett 1995;374:57-61.
10. Ito H, Kyo S, Kanaya T, Takakura M, Inoue M, Namiki M. Expression of human telomerase subunits and correlation with telomerase activity in urothelial cancer. Clin Cancer Res 1998;4:1603-1608.
11. Ohana P, Bibi O, Matouk I, et al. Use of H19 regulatory sequences for targeted gene therapy in cancer. Int J Cancer 2002; 645-650.
12. Ayesh B, Matouk I, Ohana P, et al. Inhibition of tumor growth by DT-A expressed under the control of IGF2 P3 and P4 promoter sequences. Mol Ther 2003;7:535-541.
13. Abdul-Ghani R, Ohana P, Matouk I, et al. Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. Mol Ther 2000;2:539-544.
14. Hirose M, Fukushima S, Hananouchi M, et al. Different susceptibilities of the urinary bladder epithelium of animal species to three nitroso compounds. Gann 1976;67:175-189.
15. Epstein J, Amin MB, Reuter VE, Mostofi FK. Bladder Consensus Conference Committee 1998. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998;22:1435-1438.
16. Ayesh S, Matouk I, Schneider T, et al. The possible physiological role of H19 RNA. Mol Carcinogenesis 2002;35:63-74.
17. Futscher BW, Blake LL, Gerlach JH, Grogan TM, Dalton WS. Quantitative polymerase chain reaction analysis of mdr1 mRNA in multiple myeloma cell lines and clinical specimens. Anal Biochem 1993;213:414-421.
18. Elkin M, Ayesh S, Schneider T, de Groot N, Hochberg A, Ariel I. The dynamics of the imprinted H19 gene expression in the mouse model of bladder carcinoma induced by N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis 1998;19:2095-2099.
19. Elkin M, Ariel I, Miao HQ, et al. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone. Cancer Res 1999;59:4111-4118.
20. Ohtani M, Kakizoe T, Nishio Y, et al. Sequential changes of mouse bladder epithelium during induction of invasive carcinomas by N-butyl-N-(4- hydroxybutyl)nitrosamine. Cancer Res 1986;46:2001-2004.
21. Spruck CH III, Ohneseit SP, Gonzales-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994;54:784-788.
22. Rachmilewitz J, Goshen R, Ariel I, Schneider T, de Groot N, Hochberg A. Parental imprinting of the human H19 gene. FEBS Lett. 1992;309:25-28.
23. Morison IM, Reeve AE. A catalogue of imprinted genes and parent-of-origin effects in humans and animals. Mol Hum Genet 1998;7:1599-1609.
24. Brannan CI, Dees EC, Ingram RS, Tilghman SM. The product of the H19 gene may function as an RNA. Mol Cell Biol 1990;10:28-36.
25. Ariel I, Lustig O, Schneider T, et al. The imprinted H19 gene as a tumor marker in bladder carcinoma. Urology 1995;45:335-338.
26. Wang WH, Duan JK, Vu TH, Hoffman AR. Increased expression of insulin-like growth factor-II gene in Wilms' tumor is not dependent on loss of genomic imprinting or loss of heterozygosity. J Biol Chem 1996;271:27863-27870.
27. Mineo R, Fichera E, Liang SJ, Fujita-Yamaguchi Y. Promoter usage for insulin-like growth factor-II in cancerous and benign human breast, prostate, and bladder tissues, and confirmation of a 10th exon. Biochim Biophys Res Commun 2000;268:886-892.
28. Sohda T, Yun K, Iwata K, Soejima H, Okumura M. Increased expression of insulin-like growth factor 2 in hepatocellular carcinoma is primarily regulated at the transcriptional level. Lab Invest 1996;75:307-311.
29. Cooper MJ, Fischer M, Komitowski D, et al. Developmentally imprinted genes as markers for bladder tumor progression. J Urol 1996;155:2120-2127.
30. Fichera E, Liang S, Xu Z, Guo N, Mineo R, Fujita-Yamaguchi Y. A quantitative reverse transcription and polymerase chain reaction assay for human IGF-II allows direct comparison of IGF-II mRNA levels in cancerous breast, bladder, and prostate tissues. Growth Horm IGF Res 2000;10:61-70.
31. Holthuizen PE, Cleutjens CB, Veenstra GJ, van der Lee FM, Koonen-Reemst AM, Sussenbach JS. Differential expression of the human, mouse, and rat IGF-II genes. Regul Pept 1993;48:77-89.
32. Kim NW. Clinical implications of telomerase in cancer. Eur J Cancer 1997;33:781-786.
33. Chadeneau C, Siegel P, Harley CB, Muller W, Bacchetti S. Telomerase activity in normal and malignant murine tissues. Oncogene 1995;11:893-898.
34. Blasco MA, Rizen M, Greider CW, Hanahan D. Differential regulation of telomerase activity and telomerase RNA during tumorigenesis. Nat Genet 1996;12:200-204.
35. Broccoli D, Godley LA, Donehower LA, Varmus HE, de Lange T. Telomerase activation in mouse mammary tumors: Lack of detectable telomere shortening and evidence for regulation of telomerase RNA with cell proliferation. Mol Cell Biol 1996;16:3765-3772.
36. Lavezzi AM, Biondo B, Cazzullo A, et al. The role of different biomarkers (DNA, PCNA, apoptosis, and karyotype) in prognostic evaluation of superficial transitional cell bladder carcinoma. Anticancer Res 2001;21:1279-1284.
37. Strange RC, Spiteri MA, Ramachandran S, Fryer AA. Glutathione-S- transferase family of enzymes. Mutat Res 2001;482:21-26.
38. Schnakenberg E, Breuer R, Werdin R, Dreikorn K, Schloot W. Susceptibility genes GSTM1 and GSTM3 as risk factors in bladder cancer. Cytogenet Cell Genet 2000;91:234-238.
39. Katoh T, Kaneko S, Takasawa S, et al. Human glutathione S-transferase P1 polymorphism and susceptibility to smoking related epithelial cancer: Lung, gastric, colorectal, and urothelial cancer. Parmacogenetics 1999;9:165-169.
40. Miyake H, Gleave ME, Kamidono S, Hara I. Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression recurrence. Urology 2002;59:150-154.
41. Miyake H, Hara I, Kamidono S, Gleave ME. Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in human bladder cancer model. Clin Cancer Res 2001;7:4245-4252.